Karyopharm Therapeutics Files 8-K on Financial Condition
Ticker: KPTI · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**KPTI just dropped an 8-K about their financials, expect new numbers soon.**
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' This filing, under the trading symbol KPTI on the Nasdaq Global Select Market, indicates the company is providing an update on its financial performance. For investors, this matters because it signals that new financial information, potentially impacting the company's valuation and future prospects, is being disclosed, which could influence stock price movements.
Why It Matters
This filing indicates Karyopharm Therapeutics is releasing new financial information, which could reveal insights into their recent performance and future outlook, directly affecting investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — The filing itself is administrative, but the underlying financial information it refers to could contain positive or negative news, creating market volatility.
Analyst Insight
Investors should monitor Karyopharm Therapeutics Inc. (KPTI) for the actual financial statements and results that this 8-K foreshadows, as those details will provide the real substance for investment decisions.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Karyopharm's stock is registered
- KPTI (company) — the trading symbol for Karyopharm Therapeutics Inc.
- January 8, 2024 (date) — date of earliest event reported and filing date
Forward-Looking Statements
- Karyopharm Therapeutics Inc. will release detailed financial results shortly after this 8-K filing. (Karyopharm Therapeutics Inc.) — high confidence, target: 2024-01-31
FAQ
What is the primary purpose of Karyopharm Therapeutics Inc.'s 8-K filing dated January 8, 2024?
The primary purpose of Karyopharm Therapeutics Inc.'s 8-K filing dated January 8, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' as indicated by the 'ITEM INFORMATION' sections.
What is the trading symbol and the exchange where Karyopharm Therapeutics Inc. is registered?
Karyopharm Therapeutics Inc. is registered under the trading symbol KPTI on the Nasdaq Global Select Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the state of incorporation for Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. is incorporated in Delaware, as specified in the filing under 'State or Other Jurisdiction of Incorporation'.
What is the business address and phone number of Karyopharm Therapeutics Inc.?
The business address for Karyopharm Therapeutics Inc. is 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459, and their telephone number is (617) 658-0600, according to the 'BUSINESS ADDRESS' and 'Registrant’s telephone number' sections.
What is the Central Index Key (CIK) for Karyopharm Therapeutics Inc.?
The Central Index Key (CIK) for Karyopharm Therapeutics Inc. is 0001503802, as listed under 'FILER: COMPANY DATA'.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-08 08:40:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d86824d8k.htm (8-K) — 24KB
- d86824dex991.htm (EX-99.1) — 58KB
- g86824g0106231653293.jpg (GRAPHIC) — 4KB
- 0001193125-24-003978.txt ( ) — 219KB
- kpti-20240108.xsd (EX-101.SCH) — 3KB
- kpti-20240108_lab.xml (EX-101.LAB) — 18KB
- kpti-20240108_pre.xml (EX-101.PRE) — 11KB
- d86824d8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Karyopharm Therapeutics Inc. (the "Company") announced preliminary unaudited fourth quarter and full year 2023 total revenue and U.S. XPOVIO (selinexor) net product revenue estimates, and outlined its 2023 achievements and 2024 objectives. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on January 8, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 8, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary